In response: Dr. Blinkhorn makes several comments in response to our article. Although some of the intensified tuberculosis control measures that we described were in place already, there was substantial room for improvement, even in a city with an excellent control program. Regarding the impact of HIVtuberculosis co-infection on clustering, HIV infection was not the only variable affecting clustering in our population. In fact, the rate of clustered cases decreased significantly among persons not infected with HIV or those with unknown HIV status. In addition, rates of clustering were found to decrease among persons born in the United States (a group at high risk for clustering).
We disagree that knowledge of DNA fingerprinting results will not directly affect the clustering phenomenon. For example, our experiences in San Francisco demonstrating marked clustering among HIV-infected persons and others (1, 2) were the impetus for creating several of the intensified tuberculosis control measures described in our study, including improved contact investigations, expanded use of directly observed therapy, development of an HIV-related tuberculosis prevention program, and screening for tuberculosis among persons in residential care facilities. These measures probably accounted for the marked decreases in clustered cases that we observed. Furthermore, as technology improves, the possibility of "real-time" DNA fingerprinting will become a reality (3) so that the results can directly influence tuberculosis control.
Dr. Blinkhorn also hypothesizes that clustering occurs when the source case-patient is immunocompromised or has far-advanced disease before seeking medical attention and that a tuberculosis control program cannot influence either scenario. He states that in Cleveland, secondary cases among contacts to the above persons were common because medical attention was not sought by "disenfranchised members of the community" until active tuberculosis was present. We disagree. In fact, one of our main accomplishments was in expanding the scope of our contact investigations so that we identified more contacts per case; far fewer cases had no contacts than in previous years. This was especially true among case-patients born in the United States, who frequently had a history of substance abuse, homelessness, or HIV infection. This was largely the result of intensive efforts to improve communication with these disenfranchised persons. We agree that public education regarding the symptoms of tuberculosis is important, but DNA fingerprinting is especially useful in both suggesting and evaluating methods to decrease transmission of tuberculosis. By showing only the cases and not infections, DNA fingerprinting reveals the missed opportunities for prevention of tuberculosis.
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Mycophenolate Mofetil-Induced Dyshidrotic Eczema
To the Editor: Dyshidrotic eczema is a common skin disease that accounts for 5% to 20% of cases of hand eczema. Underlying trigger mechanisms, such as allergic contact dermatitis, dermatophytosis, bacterial foci, or drug eruptions, can sometimes be detected. To our knowledge, no case of mycophenolate mofetil-induced dyshidrotic eczema has been previously reported.
In September 1996, a 45-year-old woman underwent liver transplantation for ethylic cirrhosis. The postoperative period was uneventful, and the immunosuppressive regimen consisted of cyclosporine and prednisolone. The serum creatinine level at discharge was 125 mol/L. Renal function became progressively impaired, and the serum creatinine level reached 200 mol/L in August 1997. Renal histologic findings were consistent with cyclosporine toxicity. Mycophenolate mofetil, 2 g/d, was introduced in October 1998 with the aim of allowing withdrawal of cyclosporine. Three days later, the patient reported pruritus localized on both hands. Physical examination revealed a bullous eruption on the hands and feet. Mycophenolate mofetil was immediately withdrawn, and cutaneous lesions resolved. The drug was reintroduced (500 mg/d) during hospitalization in January 1999. Therapy with the drug was stopped the following day because similar lesions developed on the patient's hands. Skin biopsy showed dyshidrotic eczema, and cutaneous allergic tests with mycophenolate mofetil reproduced the lesions.
Mycophenolate mofetil, the morpholinoethyl esther of mycophenolic acid, is a new selected immunosuppressant developed to prevent and treat acute renal rejection after transplantation. Mycophenolic acid potently, selectively, and reversibly inhibits the de novo pathway of purine synthesis in T and B cells (1, 2) . Mycophenolate mofetil has recently been used for many disorders, including dermatologic diseases (3). Of interest, a severe case of dyshidrotic eczema has been successfully treated with the drug (4).
Major adverse effects of mycophenolate mofetil include gastrointestinal tract symptoms (such as nausea and loose stools), leukopenia, and anemia (1) . No allergic or skin reactions have been reported with the use of this drug. In our case, the diagnosis of dyshidrotic eczema was confirmed by physical and histologic examination. The patient has no history of allergy or eczema. Dyshidrotic eczema occurred 72 hours after mycophenolate mofetil therapy began and resolved after withdrawal of the drug. A reintroduction trial and allergic tests with the drug confirmed the relation between the drug and skin symptoms. 
Venlafaxine-Associated Hepatitis
To the Editor: We agree with Horsmans and colleagues, who suggest that liver function should be regularly monitored in patients receiving venlafaxine. We report another case of acute hepatic injury with a prominent element of cholestasis in a patient taking this drug.
On 15 April 1999, a 78-year-old man was admitted to our hospital with icteric acute hepatitis. His medical history revealed Parkinson disease that was being treated with levodopa and pergolide and a major depression episode that had been treated with electroconvulsive therapy 2 months before admission. On 6 March, he had begun receiving venlafaxine at an initial dosage of 37.5 mg/d; this was increased to 150 mg/d on 9 April. Abdominal ultrasonography showed no anatomic abnormalities. In sharp contrast to his previous normal liver chemistry analysis, his liver function at admission showed the following abnormalities: alanine aminotransferase level, 3.97 kat/L (normal Ͻ 1.08 kat/L); aspartate aminotransferase level, 4.36 kat/L (normal Ͻ 0.62 kat/ L); ␥-glutamyltransferase level, 12.17 kat/L (normal Ͻ 1.42 kat/L); alkaline phosphatase level, 11.33 kat/L (normal Ͻ 2.27 kat/L); total bilirubin level, 87 mol/L (normal Ͻ 17.1 mol/L); and direct bilirubin level, 86 mol/L (normal Ͻ 5.5 mol/L). Serologic tests for hepatitis A, B, and C yielded negative results.
While venlafaxine therapy was progressively discontinued (the patient still received his regular therapy), the patient's health gradually improved. This improvement is supported by the fact that his liver function test results returned to normal within 5 weeks.
We conclude that it is well justified to identify venlafaxine as the culprit in the patient's acute liver toxic insult. We excluded all other possible causes of toxic hepatic injury, and liver function returned to normal after discontinuation of venlafaxine therapy. We concur with Horsmans and colleagues and strongly support their recommendation that patients taking venlafaxine be regularly monitored for liver function.
Xavier Cardona Asunción Avila Pere Castellanos
Consorci de l'Hospital de la Creu Roja Barcelona, 08906 Spain 
Hydroxyurea-Induced Leg Ulcers Treated with Apligraf
To the Editor: Hydroxyurea is an antineoplastic agent commonly used to treat myeloproliferative disorders. We report on a 74-year-old woman with a history of chronic myelocytic leukemia who was treated with hydroxyurea. During therapy, the patient developed a cutaneous ulcer on her right lateral malleolus that was accompanied by severe pain and burning at the ulcer site. Malleoli ulcers have been uncommonly reported in patients receiving hydroxyurea (1, 2). Postulated mechanisms of hydroxyurea-induced ulcers include inhibition of DNA synthesis and subsequent keratinocyte cell death. A typical feature of hydroxyurea-induced ulcer is a poor response to standard ulcer therapeutic agents, such as topical and systemic antibiotics, pentoxifylline, Unna boots, and occlusive dressings. Eventual healing of these ulcers typically requires discontinuation of hydroxyurea treatment.
We successfully treated our patient's ulcer with a single application of Apligraf (Novartis Pharmaceuticals Corp., East Hanover, New Jersey), a new tissue-engineered human skin equivalent (3). Apligraf has been approved by the U.S. Food and Drug Administration for the treatment of venous leg ulcers. Our patient's ulcer was completely healed in 3 weeks, despite concomitant chemotherapy with anagrelide. Although cessation of hydroxyurea therapy is required for healing of these difficult ulcers, complete epithelialization may still take up to 5 months with stan-dard methods (1). We believe that Apligraf is a therapeutic option for these patients. 
Understanding Adherence to HIV Medication
To the Editor: Highly active antiretroviral therapy (HAART) has been associated with reduced mortality and morbidity in HIV-infected patients (1) . Successful management of HIV relies on near-perfect adherence to complex treatment regimens. To better understand this dilemma, 35 members (including 6 physicians) of our AIDS center participated in a 2-week simulation of common antiretroviral regimens.
The study involved communicating a clinical scenario to the participants, random assignment to a mock antiretroviral regimen (stavudine, lamivudine, and indinavir; lamivudine, ritonavir, and invirase; or didanosine, stavudine, and nelfinavir), and diaries for recording daily behaviors and medication intake. After 1 week of "therapy," volunteers received a second scenario depicting clinical and virologic disease progression and were randomly changed to one of the two remaining regimens. The equivalents of the antiretroviral agents were empty gelatin capsules for the protease inhibitors indinavir, ritonavir, and invirase; vitamin C, 500 mg, for nelfinavir; calcium carbonate tablets for lamivudine; Rolaids for zidovudine; vitamin E, 100 mg, for stavudine; and calcium carbonate, 500 mg, for didanosine.
After each week, the participants recounted their experiences in videotaped debriefing sessions. Only one person was 100% adherent in the first week; most participants missed more than one dose per day. Many participants stopped taking at least one antiretroviral drug, citing difficulty swallowing many pills or somatic manifestations (headache or gastrointestinal distress). Few followed dietary restrictions and dosing intervals, noting that daily activities interfered with their regimens. Several participants became confused with their regimens and frustrated with their own poor compliance. One participant associated the regimen with being at her job; her noncompliance detached her mentally from the workplace. She followed similar patterns of denial with her own health care, understanding this to be a self-defeating approach. Despite availability of interventions to improve adherence, only 5 members used pill boxes or support networks.
This exercise represents a unique experience in listening to patients and explaining why only 35% of our patients achieve optimal results. Our anxiety with our poor compliance parallels the frustration patients feel when they too fall short of complete adherence (2) . By meeting patients on their own ground, the patient-provider relationship is actively cultivated (3). We must understand the barriers to adherence and intervene to overcome them if current antiretroviral therapy is to remain effective.
Jason M. Leider, MD, PhD
St. Luke's-Roosevelt Hospital Center New York, NY 10019
Importance of Proper Identification of Stinging Insects
To the Editor: The interesting comment from DeGrandi-Hoffman and Hoffman (1) suggest that the bee sting dysphagia described by Shah and Tsang (2) was due to a yellow jacket. Although they point out the differences between a honey bee and a yellow jacket/wasp, a few important points need to be clarified.
The authors emphasize that proper identification of stinging insects on a morphologic basis or according to history is important for desensitization. However, the guidelines for venom immunotherapy have been well established (3) . Patients, especially adults, with a systemic reaction to the stinging insect and a positive response on an allergy skin test to specific Hymenoptera venom at a concentration of 1 g/mL or less are candidates for venom immunotherapy. This applies to positive and negative identification of stinging insects. In many cases, the patient, family physician, or allergist may not be able to identify the insect. A limited number of patients are bee-keepers, and many of them are hyperimmune and do not manifest allergic reaction.
Although it is generally accepted that an embedded barbed stinger with an attached venom sac left in a sting victim is from a honey bee, this finding is not absolute proof of a honey bee because 4% to 8% cases of vespid stingers and venoms sacs also evulse (4). Hence, identification of an embedded stinger alone is not the criterion for desensitization.
According to the taxonomy of the Hymenoptera insect order, the honey bee (Apis mellifera) belongs to family Apidae, while the yellow jacket (Vespula species) and the paper wasp (Polistes species) belong to the family Vespidae. Within the family Vespidae, the yellow jacket is grouped under the subfamily Vespinae and the paper wasp is grouped under the subfamily Polistinae (5). Although they are vespids, yellow jackets differ from wasps in venom antigenicity, appearance, habitat, and aggressiveness. Hence, yellow jackets and wasps are not interchangeable. Separate and specific venoms are used in venom immunotherapy.
It is important that readers of these letters do not think that treatment (venom immunotherapy) should be based on morphologic identification, stinger, and history. Rather, an allergist should assess the patient by taking a clinical history, with emphasis on the severity of symptoms, and by performing venom testing. Only then should immunotherapy be instituted. As appropriate, the patient should be instructed to avoid stinging insects, carry an epinephrine pen, or wear a medical alert bracelet.
H.C. George Wong, MD
University of British Columbia Vancouver, British Columbia V3A 1J2, Canada bination (4, 5) . Myositis is especially undesirable in patients with underlying neuromuscular disorders. The literature contains no information on the use of statins and fibrates in such patients. We present a retrospective case series of patients with various neuromuscular disorders in whom statins, fibrates, or a combination of both was used.
Seven hyperlipidemic patients with neuromuscular disorders were treated (Table) . All had elevated creatine kinase levels before starting therapy, ranging from 239 U/L to 1921 U/L. Three patients (with minicore myopathy, myotonic dystrophy, and postpoliomyelitis syndrome, respectively) were treated with a statin for 12 to 102 months. Another patient with postpoliomyelitis syndrome was receiving a fibrate for 112 months and then a statin for 4 months. One patient (with Kugelberg-Welander disease) was treated with a fibrate for 9 months and then a statin for 4 months. Two patients (with motor neuron disease and McArdle disease, respectively) were first treated with a statin or fibrate and then with both drugs.
One patient with postpoliomyelitis syndrome reported worsening of muscle weakness while receiving fenofibrate but not while receiving clofibrate or bezafibrate. Three patients had increases in creatine kinase levels: the patients with minicore myopathy and postpoliomyelitis syndrome (while receiving a statin) and McArdle disease (while receiving a fibrate). Creatine kinase levels peaked at 1752 U/L, 2284 U/L, and 5435 U/L, respectively. However, the peaks coincided with increases in physical activity. Levels returned to baseline when activity was reduced, with continuation of therapy. No cases of rhabdomyolysis developed.
In our case series, it appears that statins and fibrates need not be totally avoided in patients with neuromuscular disorders, even when baseline creatine kinase levels are elevated. Close monitoring of muscular symptoms and signs and creatine kinase levels would be prudent.
